openPR Logo
Press release

Investigation announced for Long-Term Investors in Kiromic BioPharma, Inc. (NASDAQ: KRBP) over potential Wrongdoing

10-31-2022 07:04 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of current long term investors in Kiromic BioPharma, Inc. (NASDAQ: KRBP) shares.

An investigation on behalf of current long term investors in Kiromic BioPharma, Inc. (NASDAQ: KRBP) shares.

An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Kiromic BioPharma, Inc.

Investors who are current long term investors in Kiromic BioPharma, Inc. (NASDAQ: KRBP) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: KRBP stocks follows a lawsuit filed against Kiromic BioPharma, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: KRBP stocks, concerns whether certain Kiromic BioPharma, Inc. (NASDAQ: KRBP officers and directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the Southern District of New York the plaintiff alleges that the Offering Documents failed to disclose that the FDA had, prior to the filing of the Registration Statement and Prospectus, imposed a clinical hold, and in fact, contained statements indicating that it had not. Given that the Offering closed on July 2, 2021, more than thirty (30) days after the Company submitted the IND applications for its two immunotherapy product candidates, investors were assured that no clinical hold had been issued and clinical trials would commence.

Those who purchased shares of Kiromic BioPharma, Inc. (NASDAQ: KRBP) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Long-Term Investors in Kiromic BioPharma, Inc. (NASDAQ: KRBP) over potential Wrongdoing here

News-ID: 2785570 • Views:

More Releases from Shareholders Foundation

Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: JHX) should contact the Shareholders Foundation
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements. Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT)
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …
An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced. Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherapeutics (NASDAQ: MLTX)
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …
An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements. Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
A deadline is coming up on October 28, 2025 in the lawsuit filed for certain investors of Dow Inc. (NYSE: DOW) over alleged securities laws violations by Dow Inc. Investors who purchased shares of Dow Inc. (NYSE: DOW) have certain options and there are strict and short deadlines running. Deadline: October 28, 2025. Dow Inc. (NYSE: DOW) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -

All 5 Releases


More Releases for Kiromic

Dendritic Cell Cancer Vaccines Market 2023 | Futuristic Trends-3M Company, Activ …
The Dendritic Cell Cancer Vaccines research report combines vital data incorporating the competitive landscape, global, regional, and country-specific market size, market growth analysis, market share, recent developments, and market growth in segmentation. Furthermore, the Dendritic Cell Cancer Vaccines research report offers information and thoughtful facts like share, revenue, historical data, and global market share. It also highlights vital aspects like opportunities, driving, product scope, market overview, and driving force. Download FREE
Deadline on October 4th is coming up in Lawsuit for Investors in Kiromic BioPhar …
A deadline is coming up on October 4, 2022 in the lawsuit filed for certain investors of Kiromic BioPharma, Inc. (NASDAQ: KRBP) over alleged securities laws violations by Kiromic BioPharma, Inc. Investors who purchased shares of Kiromic BioPharma, Inc. (NASDAQ: KRBP) have certain options and there are strict and short deadlines running. Deadline: October 4, 2022. NASDAQ: KRBP stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -
Lawsuit filed for Investors in shares of Kiromic BioPharma, Inc. (NASDAQ: KRBP)
An investor, who purchased shares of Kiromic BioPharma, Inc. (NASDAQ: KRBP), filed a lawsuit over alleged violations of Federal Securities Laws by Kiromic BioPharma, Inc. in connection with certain allegedly false and misleading statements made between June 25, 2021 and August 13, 2021 and in connection with The Company's public offering closed on July 2, 2021 (the Offering). Investors who purchased shares of Kiromic BioPharma, Inc. (NASDAQ: KRBP) have certain options
Dendritic Cell Cancer Vaccine Market- Global Industry Analysis, Size, Share, Gro …
The Dendritic Cell Cancer Vaccine Market research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Get a Free Sample Copy @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=5994808 Segment by Type - CreaVax - Sipuleucel-T (Provenge) - Others Segment by Application - Pediatrics -
Investigation announced for Investors in shares of Kiromic BioPharma, Inc. (NASD …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Kiromic BioPharma, Inc. Investors who purchased shares of Kiromic BioPharma, Inc. (NASDAQ: KRBP) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Kiromic BioPharma directors breached their fiduciary duties and caused damage to the company and its shareholders. Houston, TX
Investigation announced for Investors in shares of Kiromic BioPharma, Inc. (NASD …
An investigation was announced over potential securities laws violations by Kiromic BioPharma, Inc. in connection with certain financial statements. Investors who purchased shares of Kiromic BioPharma, Inc. (NASDAQ: KRBP), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Kiromic BioPharma, Inc. regarding its business, its prospects and its operations were